Creative Biolabs offers a comprehensive suite of toxicology assessment services specifically designed to evaluate the safety profiles of therapeutic antibodies and proteins in the field of immuno-oncology, ultimately accelerating the delivery of safe and effective cancer immunotherapies.
Addressing the Unique Toxicology Challenges of Immuno-Oncology Biologics - Immuno-oncology therapeutics, while holding immense promise for cancer treatment, can elicit a range of adverse effects due to their mechanism of action. These effects can include cytokine release syndrome (CRS), immune-related adverse events (irAEs), and off-target toxicities. Creative Biolabs' toxicology services are specifically designed to address these unique challenges, ensuring a thorough understanding of the potential risks associated with your antibody or protein therapeutic.
Creative Biolabs' offers in vitro and in vivo toxicology assays that enable a comprehensive understanding of the toxicity of your antibody or protein therapeutic:
- Cell-Based Assays: In vitro assays including cytotoxicity assays, cytokine release assays, and mixed lymphocyte reactions to assess the direct and indirect effects of the therapeutic on immune cells.
- In Vivo Toxicology Studies: Creative Biolabs offers a range of in vivo toxicology studies in relevant animal models to assess systemic toxicity, target organ toxicity, and immune-related adverse events.
- Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) Assays: Evaluation of ADCC activity to assess the potential for off-target cell lysis.
- Complement-Dependent Cytotoxicity (CDC) Assays: Assessment of CDC activity to identify potential complement-mediated toxicities.
- Cytokine Release Syndrome (CRS) Assays: In vitro and in vivo assays to assess the risk of CRS, a potentially life-threatening systemic inflammatory response.
Beyond Standard Toxicology: Tailored Solutions for Immuno-Oncology - Understanding that each immuno-oncology therapeutic presents unique toxicology challenges, Creative Biolabs specializes in developing customized study designs tailored to your specific molecule and target. This includes:
- Selection of relevant cell lines and animal models: Careful consideration of target expression, immune system functionality, and pharmacokinetic/pharmacodynamic (PK/PD) properties to ensure the most relevant model for your therapeutic.
- Development of novel assays: Creative Biolabs can develop novel assays to address specific toxicology concerns related to your therapeutic's mechanism of action.
- Comprehensive data analysis and interpretation: Expert analysis of toxicology data to identify potential risks and inform decision-making.
Partnering for Success: Expertise and Quality You Can Trust - Creative Biolabs brings to your project extensive experience in antibody and protein therapeutics development, coupled with a deep understanding of immuno-oncology. Our commitment to quality ensures reliable and reproducible results, enabling you to make informed decisions and accelerate the development of safe and effective cancer immunotherapies. Choosing Creative Biolabs, you can be confident that your antibody or protein therapeutic will undergo rigorous toxicology assessment, minimizing risks and maximizing the chances of success. Contact us today to discuss your specific toxicology needs and learn how they can help you advance your immuno-oncology program.